Daan De Maeseneer

Head

AZ Sint-Lucas

Belgium

Research Interests

Explore related searches

Professors in Belgium

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Daan De Maeseneer is the Head at AZ Sint-Lucas in Belgium. His research focuses on the intersection of radiotherapy and systemic therapies, particularly in oncology, as evidenced by his recent articles exploring advanced solid tumors, bladder cancer, and prostate cancer treatment strategies. He is actively involved in clinical trials and guidelines to enhance patient care in these areas.

Articles (8)

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Collaborators (2)

Pieter Mestdagh

Ghent University

BELGIUM

View details

Vibeke Kruse

Guest Professor

Ghent University

BELGIUM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Daan De Maeseneer

Research Interests

Explore related searches

Contact this professor

About

Articles (8)

Checkpoint Inhibitors in Combination with Stereotactic Body Radiotherapy in Patients with Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial

Radiotherapy Use in Muscle-Invasive Bladder Cancer: Review of the Guidelines and Impact of Increased Awareness in Patient Referral at a Tertiary Center in Belgium

The Changing Landscape of Systemic Therapy in the Treatment of Synchronous Metastatic Hormone-sensitive Prostate Cancer

Adjuvant Radiotherapy After Radical Cystectomy for Patients with High-risk Muscle-invasive Bladder Cancer: Results of a Multicentric Phase II Trial

Prospective non-interventional BELOVA/BGOGov16 study on safety of frontline bevacizumab in elderly patients with FIGO stage IV ovarian cancer: a study of the Belgian and Luxembourg Gynaecological Oncology Group

Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS): study protocol for a phase 2, open-label, randomized controlled trial.

Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial

Targeting FGFR in bladder cancer: ready for clinical practice?

Collaborators (2)

Pieter Mestdagh

Vibeke Kruse

Make your next move.